Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines

British Journal of Pharmacology

Volumn 161, Issue 3, 2010, Pages 481-487

  Kast, R E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

5 HT 7; chemotherapy; ERK1 2; glioblastoma; interleukin 6; necrosis; paliperidone; pimozide; risperidone; serotonin receptors

Indexed keywords

CYCLIC AMP; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; PALIPERIDONE; PIMOZIDE; PROTEIN BCL 2; RISPERIDONE; SEROTONIN 7 RECEPTOR; STAT3 PROTEIN;

AKATHISIA; APOPTOSIS; CANCER CELL CULTURE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; GALACTORRHEA; GENE AMPLIFICATION; GLIOBLASTOMA; HUMAN; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIPSYCHOTIC AGENTS; CHEMOTHERAPY, ADJUVANT; GLIOBLASTOMA; HUMANS; INTERLEUKIN-6; MODELS, BIOLOGICAL; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION;

EID: 77956331790     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00923.x     Document Type: Review

References (52)

1. 7.
2. Angileri FF, Aguennouz M, Conti A, La Torre D, Cardali S, Crupi R et al. (2008). Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer 112 : 2258 2266.
3. Brantley EC, Benveniste EN (2008). Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 6 : 675 684.
4. Calzolari A, Larocca LM, Deaglio S, Finisguerra V, Boe A, Raggi C et al. (2010). Transferrin receptor 2 is frequently and highly expressed in glioblastomas. Transl Oncol 3 : 123 134.
5. Candi E, Knight RA, Spinedi A, Guerrieri P, Melino G (1997). A possible growth factor role of IL-6 in neuroectodermal tumours. J Neurooncol 31 : 115 122.
6. Chang CY, Li MC, Liao SL, Huang YL, Shen CC, Pan HC (2005). Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci 12 : 930 933.
7. Choi C, Gillespie GY, Van Wagoner NJ, Benveniste EN (2002). Fas engagement increases expression of IL-6 in human glioma cells. J Neurooncol 56 : 13 19.
8. Degterev A, Yuan J (2008). Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 9 : 378 390.
9. Gessi S, Sacchetto V, Fogli E, Merighi S, Varani K, Baraldi PG et al. (2010). Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A(3) adenosine receptors. Biochem Pharmacol 79 : 1483 1495.
10. Goswami S, Gupta A, Sharma SK (1998). IL-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J Neurochem 71 : 1837 1845.
11. Hannon J, Hoyer D (2008). Molecular biology of 5-HT receptors. Behav Brain Res 195 : 198 213.
12. Hirst WD, Price GW, Rattray M, Wilkin GP (1997). Identification of 5-hydroxytryptamine receptors positively coupled to adenylyl cyclase in rat cultured astrocytes. Br J Pharmacol 120 : 509 515.
13. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, Nguyen G, Wostl W, Maerki HP et al. (2004). Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 90 : 1059 1068.
14. Kast RE (2000). Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP. Int J Immunopharmacol 22 : 1001 1006.
15. Kast RE (2005). Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities - the role of bupropion. Leuk Res 29 : 1459 1463.
16. Kast RE (2007). Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications. Med Oncol 24 : 1 6.
17. Kast RE (2009). Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA approved antiemetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis answering an old question. Clin Transl. Oncology 11 : 408 410.
18. Kast RE (2010). Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. J Clin Pharm Ther DOI: 10.1111/j.1365-2710.2009.01148.x [Epub ahead of print
19. Kast RE, Altschuler EL (2006). Current drugs available now for interleukin-6 suppression as treatment adjunct in gllioblastoma: anakinra, aprepitant, mirtazapine and olanzapine. Int J Cancer Res 2 : 303 314.
20. Kim JY, Kim YJ, Lee S, Park JH (2009). The critical role of ERK in death resistance and invasiveness of hypoxia selected glioblastoma cells. BMC Cancer 9 : 27.
21. Kudo M, Jono H, Shinriki S, Yano S, Nakamura H, Makino K et al. (2009). Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. J Neurosurg 111 : 219 225.
22. 7 receptors activates p38 mitogen-activated protein kinase and protein kinase C epsilon resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells. J Neurochem 93 : 549 559.
23. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA et al. (2009). L-Thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 296 : C980 C991.
24. Liu Q, Li G, Li R, Shen J, He Q, Deng L et al. (2010). IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol Epub ahead of print] PubMed PMID: 20361349.
25. Loeffler S, Fayard B, Weis J, Weissenberger J (2005). Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 115 : 202 213.
26. Loew S, Schmidt U, Unterberg A, Halatsch ME (2009). The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem 9 : 703 715.
27. Lopez-Gines C, Gil-Benso R, Benito R, Mata M, Pereda J, Sastre J et al. (2008). The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathology 28 : 507 515.
28. 7 receptor in human glioblastoma cell lines. Br J Pharmacol 143 : 404 410.
29. Marino J, Caballero J (2008). Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 28 : 1283 1298.
30. Maru SV, Holloway KA, Flynn G, Lancashire CL, Loughlin AJ, Male DK et al. (2008). Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. J Neuroimmunol 199 : 35 45.
31. Möller HJ (2005). Risperidone: a review. Expert Opin Pharmacother 6 : 803 818.
32. Opler LA, Feinberg SS (1991). The role of pimozide in clinical psychiatry: a review. J Clin Psychiatry 52 : 221 233.
33. Owens DG (1994). Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 55 : 29 35.
34. Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G (2007). 5-HT7 receptor ligands: recent developments and potential therapeutic applications. Mini Rev Med Chem 7 : 945 960.
35. Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M et al. (2005). Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 308 : 241 253.
36. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ (2002). Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21 : 8404 8413.
37. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M et al. (2007). Occupancy of dopamine D(1), D (2) and serotonin(2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl) 190 : 241 249.
38. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr., Shen Y et al. (1994). Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268 : 1403 1410.
39. Samaras V, Piperi C, Korkolopoulou P, Zisakis A, Levidou G, Themistocleous MS et al. (2007). Application of the ELISPOT method for comparative analysis of IL-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol Cell Biochem 304 : 343 351.
40. Samaras V, Piperi C, Levidou G, Zisakis A, Kavantzas N, Themistocleous MS et al. (2009). Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, COX-2, VEGF, and microvessel morphometry. Hum Immunol 70 : 391 397.
41. Sasaki A, Ishiuchi S, Kanda T, Hasegawa M, Nakazato Y (2001). Analysis of interleukin-6 gene expression in primary human gliomas, glioblastoma xenografts, and glioblastoma cell lines. Brain Tumor Pathol 18 : 13 21.
42. Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K, Teitler M (2006). Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor. Mol Pharmacol 70 : 1264 1270.
43. Soga F, Katoh N, Inoue T, Kishimoto S (2007). Serotonin activates human monocytes and prevents apoptosis. J Invest Dermatol 127 : 1947 1955.
44. Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H et al. (2007). Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21 : 98 111.
45. Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A et al. (2008). Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 105 : 10703 10708.
46. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC et al. (2008). Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27 : 6646 6656.
47. Tchirkov A, Rolhion C, Bertrand S, Doré JF, Dubost JJ, Verrelle P (2001). IL-6 gene amplification and expression in human glioblastomas. Br J Cancer 85 : 518 522.
48. Thomas DR, Hagan JJ (2004). 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord 3 : 81 90.
49. Tueth MJ, Cheong JA (1993). Clinical uses of pimozide. South Med J 86 : 344 349.
50. Xu L, Fukumura D, Jain RK (2002). Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem 277 : 11368 11374.
51. Yip KW, Reed JC (2008). Bcl-2 family proteins and cancer. Oncogene 27 : 6398 6406.
52. Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M (2009). Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res 29 : 119 123.